en English
af Afrikaanssq Shqipam አማርኛar العربيةhy Հայերենaz Azərbaycan dilieu Euskarabe Беларуская моваbn বাংলাbs Bosanskibg Българскиca Catalàceb Cebuanony Chichewazh-CN 简体中文zh-TW 繁體中文co Corsuhr Hrvatskics Čeština‎da Dansknl Nederlandsen Englisheo Esperantoet Eestitl Filipinofi Suomifr Françaisfy Fryskgl Galegoka ქართულიde Deutschel Ελληνικάgu ગુજરાતીht Kreyol ayisyenha Harshen Hausahaw Ōlelo Hawaiʻiiw עִבְרִיתhi हिन्दीhmn Hmonghu Magyaris Íslenskaig Igboid Bahasa Indonesiaga Gaeligeit Italianoja 日本語jw Basa Jawakn ಕನ್ನಡkk Қазақ тіліkm ភាសាខ្មែរko 한국어ku كوردی‎ky Кыргызчаlo ພາສາລາວla Latinlv Latviešu valodalt Lietuvių kalbalb Lëtzebuergeschmk Македонски јазикmg Malagasyms Bahasa Melayuml മലയാളംmt Maltesemi Te Reo Māorimr मराठीmn Монголmy ဗမာစာne नेपालीno Norsk bokmålps پښتوfa فارسیpl Polskipt Portuguêspa ਪੰਜਾਬੀro Românăru Русскийsm Samoangd Gàidhligsr Српски језикst Sesothosn Shonasd سنڌيsi සිංහලsk Slovenčinasl Slovenščinaso Afsoomaalies Españolsu Basa Sundasw Kiswahilisv Svenskatg Тоҷикӣta தமிழ்te తెలుగుth ไทยtr Türkçeuk Українськаur اردوuz O‘zbekchavi Tiếng Việtcy Cymraegxh isiXhosayi יידישyo Yorùbázu Zulu

New Research: 10-Year Study Supports Effectiveness of SBRT for Early-Stage Lung Cancer

Researchers at the Cleveland Clinic recently released data from a decade-long study that followed long-term toxicity results in patients treated with stereotactic body radiation therapy for medically inoperable, early-stage lung cancer. 

Over this ten-year period, 300 patients and a total of 340 lesions were treated with SBRT. The collected data showed that only 13 percent of patients treated with SBRT had any form of toxicity related to the treatment throughout the duration of the study.   

The results from this study provided substantial evidence that treatment with SBRT for early-stage lung cancer results in no high-grade toxicity in the majority of patients treated and provides additional support for SBRT as a viable treatment option for this type of disease.  

Click here to read the full results of the study. 

Oklahoma CyberKnife treats primary, recurrent and metastatic lung tumors with CyberKnife® technology, an advanced radiosurgery platform that delivers tightly controlled, high-dose radiation without sedation or incisions. For patients with medically inoperable lung tumors who are seeking a treatment method with a low impact on quality of life, treatment with CyberKnife may be an important option. 

This is not intended as medical advice to replace the expertise and judgment of your health care team. It is intended to help you and your family make informed decisions, together with your doctor.